Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2017 | Original Article

The prognostic and predictive value of sstr₂-immunohistochemistry and sstr₂-targeted imaging in neuroendocrine tumors

Authors: Philippe Brunner, Ann-Catherine Jörg, Katharina Glatz, Lukas Bubendorf, Piotr Radojewski, Maria Umlauft, Nicolas Marincek, Petar-Marko Spanjol, Thomas Krause, Rebecca A. Dumont, Helmut R. Maecke, Jan Müller-Brand, Matthias Briel, Anja Schmitt, Aurel Perren, Martin A. Walter

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2017

Abstract

Purpose

Our aim was to assess the prognostic and predictive value of somatostatin receptor 2 (sstr₂) in neuroendocrine tumors (NETs).

Methods

We established a tissue microarray and imaging database from NET patients that received sstr₂-targeted radiopeptide therapy with yttrium-90-DOTATOC, lutetium-177-DOTATOC or alternative treatment. We used univariate and multivariate analyses to identify prognostic and predictive markers for overall survival, including sstr₂-imaging and sstr₂-immunohistochemistry.

Results

We included a total of 279 patients. In these patients, sstr₂-immunohistochemistry was an independent prognostic marker for overall survival (HR: 0.82, 95 % CI: 0.67 – 0.99, n = 279, p = 0.037). In DOTATOC patients, sstr₂-expression on immunohistochemistry correlated with tumor uptake on sstr₂-imaging (n = 170, p < 0.001); however, sstr₂-imaging showed a higher prognostic accuracy (positive predictive value: +27 %, 95 % CI: 3 – 56 %, p = 0.025). Sstr₂-expression did not predict a benefit of DOTATOC over alternative treatment (p = 0.93).

Conclusions

Our results suggest sstr₂ as an independent prognostic marker in NETs. Sstr₂-immunohistochemistry correlates with sstr₂-imaging; however, sstr₂-imaging is more accurate for determining the individual prognosis.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26:2124–30. doi:10.1200/JCO.2007.15.2553.CrossRef

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:2416–23. doi:10.1200/JCO.2010.33.7873.CrossRef

Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:1100–6. doi:10.1200/JCO.2011.37.2151.CrossRef

Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QK, et al. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:214–22. doi:10.1007/s00259-013-2559-8.CrossRefPubMed

Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146:453–60. doi:10.1053/j.gastro.2013.10.020. e5.CrossRefPubMed

Iten F, Muller B, Schindler C, Rochlitz C, Oertli D, Macke HR, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res: Off J Am Assoc Cancer Res. 2007;13:6696–702. doi:10.1158/1078-0432.CCR-07-0935.CrossRef

Iten F, Muller B, Schindler C, Rasch H, Rochlitz C, Oertli D, et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer. 2009;115:2052–62. doi:10.1002/cncr.24272.CrossRefPubMed

Korner M, Waser B, Schonbrunn A, Perren A, Reubi JC. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol. 2012;36:242–52. doi:10.1097/PAS.0b013e31823d07f3.CrossRefPubMedPubMedCentral

Rindi G, Arnold R, Bosman F, Capella C, Klimstra D. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman F, Hruban R, Theise N, editors. WHO classification of tumors of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010. p. 13–4.

10.

Moskowitz CS, Pepe MS. Quantifying and comparing the accuracy of binary biomarkers when predicting a failure time outcome. Stat Med. 2004;23:1555–70. doi:10.1002/sim.1747.CrossRefPubMed

11.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol. 2005;2:416–22.CrossRefPubMed

12.

Kim HS, Lee HS, Kim WH. Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors. Cancer Res Treat: Off J Kor Cancer Assoc. 2011;43:181–8. doi:10.4143/crt.2011.43.3.181.CrossRef

13.

Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26:963–70. doi:10.1200/JCO.2007.12.7431.CrossRef

14.

Strosberg JR, Wolin EM, Chasen B, Kulke MH, Bushnell DL, Caplin ME, et al. NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. J Clin Oncol: Off J Am Soc Clin Oncol. 2016;34.

15.

Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikolajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788–97. doi:10.1007/s00259-011-1833-x.CrossRefPubMedPubMedCentral

Title: The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors
Authors: Philippe Brunner
Ann-Catherine Jörg
Katharina Glatz
Lukas Bubendorf
Piotr Radojewski
Maria Umlauft
Nicolas Marincek
Petar-Marko Spanjol
Thomas Krause
Rebecca A. Dumont
Helmut R. Maecke
Jan Müller-Brand
Matthias Briel
Anja Schmitt
Aurel Perren
Martin A. Walter
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3486-2

At a glance: The STEP trials

Springer Medicine

The prognostic and predictive value of sstr₂-immunohistochemistry and sstr₂-targeted imaging in neuroendocrine tumors

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

Intra-lesional spatial correlation of static and dynamic FET-PET parameters with MRI-based cerebral blood volume in patients with untreated glioma

Erratum to: Role of PET/CT in malignant pediatric lymphoma

Intraindividual tumor heterogeneity in NET – Further insight by C-X-C motif chemokine receptor 4-directed imaging

Radiosynoviorthesis in hemophilic arthropathy: pathologic blood pool imaging on pre-therapeutic bone scintigraphy is not a predictor of treatment success

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism